Aug 16, 2010 by Brian Orelli, PhDThe Fine Line Between Saving Money and Making ItMedco's trying to walk it.
Aug 13, 2010 by Brian Orelli, PhDAlready a Slippery Slope for Eli LillyThe company gets a whiff of what its patent cliff might be like.
Aug 12, 2010 by Brian Orelli, PhDTurnaround Signal, or Just Noise on the Decline?Boston Scientific clears up an FDA warning letter -- four years later.
Aug 12, 2010 by Brian Orelli, PhDPfizer: Strengths, Weaknesses, Opportunities, ThreatsKnowing them all makes it easier to judge an investment.
Aug 11, 2010 by Brian Orelli, PhDDang! This Drug Is Shining BrighterVertex illuminates telaprevir's additional benefit in treating hepatitis C patients.
Aug 11, 2010 by Brian Orelli, PhDAmgen Comes Up a Little ShortVectibix improves survival, but not by enough.
Aug 10, 2010 by Brian Orelli, PhDElan's Alternative to Strategic AlternativesSometimes doing nothing is the best option.
Aug 10, 2010 by Brian Orelli, PhDWhen the Disease Matters Most in Drug ApprovalGlaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow.
Aug 9, 2010 by Brian Orelli, PhDDendreon's in TroubleProvided you call a slap on the wrist from the FDA "trouble."
Aug 5, 2010 by Brian Orelli, PhDBlockbuster Efficacy! Not-So-Blockbuster Safety!Isis and Genzyme's wonder drug has not-so-wonderful side effects. Still.
Aug 4, 2010 by Brian Orelli, PhDDendreon Doubles UpThe biotech enjoys twice as much revenue month over month.
Aug 4, 2010 by Brian Orelli, PhDNo Nail Yet, but Vertex Creeps Up to Merck's CoffinMerck's hepatitis C data doesn't look as good as Vertex's.
Aug 3, 2010 by Brian Orelli, PhDDrama Continues: What's Genzyme Worth to Sanofi?Just get on with it, Sanofi and Genzyme.
Jul 30, 2010 by Brian Orelli, PhDOn the Path to a BlockbusterAmgen's Prolia will be a blockbuster. Eventually.
Jul 30, 2010 by Brian Orelli, PhDMannKind: Strengths, Weaknesses, Opportunities, ThreatsIt's all about the inhaled insulin.
Jul 30, 2010 by Brian Orelli, PhD3 Development-Stage Drugmakers Worth WatchingA basket of potential drugs in just one company.
Jul 30, 2010 by Brian Orelli, PhDIt's Hard to Get Excited About 92% Revenue GrowthEspecially when revenue dropped on a comparable basis.
